Plain-English translation of NCT05638867 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Coronary Artery Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
After a heart attack, doctors typically give patients two blood-thinning medications to prevent clots around their stent. This trial is testing whether adding a third medication called rivaroxaban for the first three months — on top of the standard two medications — can further reduce the risk of another heart attack or stroke. The study wants to know if this extra protection is safe and doesn't cause too much bleeding.
Some patients who have had a heart attack remain at high risk for another one, even on standard treatment. Researchers believe that adding this medication temporarily might give extra protection for those highest-risk patients, but they need to make sure the benefit outweighs any increased bleeding risk.
You likely qualify if…
You likely don't qualify if…
If you are randomly chosen for the treatment group, you will take three blood-thinning medications (aspirin, clopidogrel, and rivaroxaban) for the first three months, then continue with just two medications (aspirin and clopidogrel) for the remaining nine months. If you are in the standard group, you will take only the two standard medications for the full 12 months. You will have five follow-up visits or phone calls over the year to check on your health, symptoms, and any bleeding or heart problems.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China